Association between a CYP3A4 genetic variant and clinical presentation in African-American prostate cancer patients

Cancer Epidemiology Biomarkers and Prevention

Volumn 8, Issue 10, 1999, Pages 901-905

  Paris, Pamela L ^a   Kupelian, Patrick A ^a   Hall, Jeffrey M ^b   Williams, Teri L ^b   Levin, Howard ^a   Klein, Eric A ^a   Casey, Graham ^a   Witte, John S ^c  

^a LERNER RESEARCH INSTITUTE   (United States)

^b PPGx Inc   (United States)

^c CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450; DNA; TESTOSTERONE;

ADULT; AGED; ARTICLE; CANCER EPIDEMIOLOGY; CANCER GRADING; CANCER STAGING; DNA SEQUENCE; ETHNIC GROUP; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; NEGRO; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE CANCER;

ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGED; CALIFORNIA; CYTOCHROME P-450 ENZYME SYSTEM; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; NEOPLASM STAGING; PROSTATIC NEOPLASMS; VARIATION (GENETICS);

EID: 0032756477     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Landis, S. H., Murray, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1998. CA Cancer J. Clin., 48: 6-29, 1998.
2. Miller, B. A., Kolonel, L. N., Bernstein, L., Young, J. L., Jr. Swanson, G. M., West, D., Key, C. R., Liff, J. M., Glover, C. S., and Alexander, G. A. Racial/ Ethnic Patterns of Cancer in the United States 1988-1992, National Cancer Institute, NIH Publ. No. 96-4104, Belhesda, MD, 1996.
3. Powell, I. J., Schwartz, K., and Hussain, M. Removal of the financial barrier to health care: does it impact on prostate cancer at presentation and survival? A comparative study between black and white men in a Veterans Affairs system. Urology, 46: 825-830, 1995.
4. Robbins, A. S., Whittemore, A. S., and Van Den Eeden, S. K. Race, prostate cancer survival, and membership in a large health organization. J. Natl. Cancer Inst., 90: 986-990, 1998.
5. Waxman, D. J., Attisano, C., Guengerich, F. P., and Lapenson, D. P. Human liver microsomal steroid metabolism: identification of the major microsomal steroid hormone 6B hydroxylase cytochrome P-450 enzyme. Arch. Biochem. Biophys., 263: 424-436, 1988.
6. Waxman, D. J., Lapenson, D. P., Aoyama, T., Gelboin, H. V., Gonzalez, F. J., and Korzekwa, K. Steroid hormone hydroxylase specificities of eleven cDNA-expressed human cytochrome P450s. Arch. Biochem. Biophys., 290: 160-166. 1991.
7. Rebbeck, T. R., Jaffe, J. M., Walker, A. H., Wein, A. J., and Malkowicz, S. B. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4. J. Natl. Cancer Inst., 90: 1225-1229, 1998.
8. Gleason, D. F. Histologic grading of prostate cancer-A perspective. Hum. Pathol., 23: 273-279, 1992.
9. Spiessl, B. (ed.), TNM Atlas, Ed. 3, pp. 241-250. New York: Springer-Verlag, 1992.
10. Heid, C. A., Stevens, J., Livak, K. J., and Williams, P. M. Real time quantitative PCR. Genome Res., 6: 986-994, 1996.
11. Hashimoto, H., Toide, K., Kitamura, R., Fujita, M., Tagawa, S., Itoh, S., and Kamataki, T. Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. Eur. J. Biochem. 218: 585-595, 1993.
12. Walker, A. H., Jaffe, J. M., Gunasegaram, S., Cummings, S. A., Huang, C., Chern, H., Olopade, O. I., Weber, B. L., and Rebbeck, T. R. Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Human Mutation, Mutation in Brief #191, URL: http://journals.wiley.com/1059-7794/pdf/mutation/191.pdf, 1998.
13. Coffey, D. S. Androgen action and the sex accessory tissues. In: E. Knobil, J. J. Neill, and L. L. Ewing (eds.), The Physiology of Reproduction, pp. 1081-1118. New York: Raven Press, 1988.
14. Vermeulen, A. Androgens in male senescence. In: E. Nieschlag and H. M. Behre (eds.), Testosterone: Action, Deficiency, Substitution, pp. 261-276. Berlin: Springer-Verlag, 1980.
15. Smith, J. R., Freije, D., Carpten, J. D., Gronberg, H., Xu, J., Isaacs, S. D., Brownstein, M. J., Bova, G. S., Guo, H., Bujnovszky, P., Nusskern, D. R., Damber, J. E., Bergh, A., Emanuelsson, M., Kallioniemi, O. P., Walker-Daniels, J., Bailey-Wilson, J. E., Beaty, T.H., Meyers, D. A., Walsh, P. C., Collins, F. S., Trent, J. M., and Isaacs, W. B. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science (Washington DC), 274: 1371-1374, 1996.
16. Godley, P. A., and Schnell, M. J. Adjusted odds ratios under nondifferential misclassification: applications to prostate cancer. J. Clin. Epidemol., 52: 129-136, 1999.
17. Felix, C. A., Walker, A. H., Lange, B. J., Williams, T. M., Winick, N. J., Cheung, N. V., Lovett, B. D., Nowell, P. C., Blair, I. A., and Rebbeck, T. R. Association of CYP3A4 genotype with treatment-related leukemia. Proc. Natl. Acad. Sci. USA, 95: 13176-13181, 1998.